Clinical and angiographic outcomes of very long drug eluting stents in patients with coronary artery disease undergoing percutaneous coronary intervention: a prospective observational study
DOI:
https://doi.org/10.18203/2320-6012.ijrms20262184Keywords:
Very long drug eluting stents, Stent thrombosis, Percutaneous coronary intervention, Coronary artery disease, Major adverse cardiac eventsAbstract
Background: To evaluate the procedural feasibility and clinical and angiographic outcomes of very long drug-eluting stents (DES) in patients with diffuse coronary artery disease undergoing percutaneous coronary intervention (PCI).
Methods: This observational study included 111 consecutive adult patients with de novo long coronary lesions treated with DES ≥48 mm between March 2018 and September 2019 at the Department of Cardiology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow. Clinical outcomes at 1 and 6 months included major adverse cardiac events (MACE) such as myocardial infarction, angina and congestive heart failure. Angiographic outcomes at 6 months included in-stent restenosis, target lesion revascularization, target vessel revascularization and stent thrombosis.
Results: No significant correlation was observed between clinico-angiographic outcomes and stent length, stent diameter, stent polymer, multi-vessel PCI or diabetic status (p>0.05). However, diabetic status significantly affected clinical outcomes at 6 months (p=0.020). The incidence of angina was significantly higher at 6 months compared with 1 month. Survival analysis at 1 and 6 months showed no significant difference in patient survival (p=0.778).
Conclusions: Very long DES implantation for diffuse coronary lesions appears safe and effective, with low rates of adverse clinical and angiographic events. Stent length, diameter and polymer type did not significantly influence outcomes.
References
Gupta R, Mohan I, Narula J. Trends in coronary heart disease epidemiology in India. Ann Glob Health. 2016;82(2):307–15.
Registrar General of India. Causes of deaths in India, 2001–2003. New Delhi: Office of the Registrar General. 2009.
Mohan V, Deepa R, Rani SS, Premalatha G. Prevalence of coronary artery disease and its relationship to lipids in a selected population in South India. J Am Coll Cardiol. 2001;38:682–7.
Xu B, Gao RL, Zhang RY. Efficacy and safety of FIREHAWK abluminal groove filled biodegradable polymer sirolimus-eluting stents for long coronary lesions: TARGET I trial. Chin Med J (Engl). 2013;126(6):1026–32.
Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics of the COURAGE trial. Am J Cardiol. 2007;99:208–12.
Violini R, Musto C, De Felice F, Nazzaro MS, Cifarelli A, De Luca L, et al. Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction: SESAMI trial. J Am Coll Cardiol. 2010;55:810–14.
Alfonso F, Perez-Vizcayno MJ, Hernandez R, Bethencourt A, Marti V, Lopez-Minguez JR, et al. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: RIBS-II trial. J Am Coll Cardiol. 2006;47:2152–60.
Alfonso F, Perez-Vizcayno MJ, Hernandez R, Bethencourt A, Marti V, Lopez-Minguez JR, et al. Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis: RIBS-II study. J Am Coll Cardiol. 2008;52:1621–7.
Siontis GCM, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, Perez-Vizcayno MJ, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet. 2015;386:655–64.
Rathore S, Terashima M, Katoh O, Matsuo H, Tanaka N, Kinoshita Y, et al. Predictors of angiographic restenosis after drug-eluting stents in the coronary arteries: contemporary practice in real-world patients. EuroIntervention. 2009;5:349–54.
Kini AS. Coronary angiography, lesion classification and severity assessment. Cardiol Clin. 2006;24(2):153–62.
Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going. Eur Heart J. 2015;36:3320–31.
Patted SV. Treatment of long coronary lesions with single stent: BioMime Morph sirolimus-eluting tapered coronary stent system. Heart India. 2018;6:113–4.
Ramakrishnan S, Mishra S, Chakraborty R, Chandra KS, Mardikar HM, Nair T, et al. The report on the Indian coronary intervention data for the year 2011: National Interventional Council. Indian Heart J. 2013;65:518–21.
Iragavarapu T, Radhakrishna T, Babu KJ, Sanghamitra R, Kiranmayi VS, Kumar RV. Acute coronary syndrome in young: a tertiary care centre experience with reference to coronary angiogram. J Pract Cardiovasc Sci. 2019;5:18–25.
Mahalle N, Garg MK, Naik SS, Kulkarni MV. Study of pattern of dyslipidemia and its correlation with cardiovascular risk factors in patients with proven coronary artery disease. Indian J Endocrinol Metab. 2014;18(1):48–55.
Bhalodkar NC, Blum S, Rana T, Kitchin AH, Bhatia S, Bhalodkar AN. Comparison of levels of large and small high-density lipoprotein cholesterol in Asian Indian men compared with Caucasian men in the Framingham offspring study. Am J Cardiol. 2004;94:1561–3.
Schomig A, Mehilli J, Holle H, Kastrati A, Dirschinger J, Schühlen H, et al. Statin treatment following coronary artery stenting and one-year survival. J Am Coll Cardiol. 2002;40:854–61.
Sinha SK, Krishna V, Thakur R, Kumar A, Mishra V, Jha MJ, et al. Acute myocardial infarction in very young adults: clinical presentation, risk factors, hospital outcome index and angiographic characteristics: AMIYA study. ARYA Atheroscler. 2017;13(2):79–87.
Thygesen K, Alpert JS, Jaffe AS, White HD, Apple FS, Galvani M, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33(20):2551–67.
Gopalan Nair R, Rajesh S, Sulaiman M, Thajudeen A, Namboodiri N, Sivaprasad K, et al. One-year clinical outcome of percutaneous coronary intervention with very long (≥40 mm) drug-eluting stent. Indian Heart J. 2018;70(3):285–9.
Lee MS, Shlofmitz R, Mahmud E, Cox D, Hermiller J, Pinto DS, et al. Four-year outcomes of multivessel percutaneous coronary intervention with Xience V everolimus-eluting stents. J Invasive Cardiol. 2019;31(9):240–6.
Zhao L, Zhu W, Zhang X, He B, Li J, Liu J, et al. Effect of diabetes mellitus on long-term outcomes after repeat drug-eluting stent implantation for in-stent restenosis. BMC Cardiovasc Disord. 2017;17:16.
Genuardi L, Burzotta F, Russo G, Trani C, Brancati MF, Niccoli G, et al. Novel ultra-long (48 mm) everolimus-eluting stent for diffusely diseased coronary vessels. Minerva Cardioangiol. 2019;67(2):87–93.
Chang SH, Chen CC, Hsieh MJ, Lee CH, Chen DY, Hsieh IC, et al. Lesion length impacts long-term outcomes of drug-eluting stents and bare metal stents differently. PLoS One. 2013;8(1):53207.
Virmani R, Farb A, Guagliumi G, Kolodgie FD. Drug-eluting stents: caution and concerns for long-term outcome. Coron Artery Dis. 2004;15:313–8.
Meredith IT, Verheye S, Dubois CL, Dens J, Farah B, Carrié D, et al. Primary endpoint results of the EVOLVE trial: randomized evaluation of a novel bioabsorbable polymer-coated everolimus-eluting coronary stent. J Am Coll Cardiol. 2012;59:1362–70.
Smits PC, Hofma S, Togni M, Vázquez N, Valdés M, Percoco G, et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: COMPARE II trial. Lancet. 2013;381:651–60.
Windecker S, Haude M, Neumann FJ, Stangl K, Skurk C, Slagboom T, et al. Comparison of biodegradable polymer sirolimus-eluting stent with durable polymer everolimus-eluting stent: BIOFLOW-II trial. Circ Cardiovasc Interv. 2015;8:1441.
Saito S, Valdes-Chavarri M, Richardt G, Moreno R, Iniguez A, Barbato E, et al. Clinical evaluation of new terumo drug-eluting coronary stent system: CENTURY II trial. Eur Heart J. 2014;35:2021–3
Downloads
Published
How to Cite
Issue
Section
